Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V4020 Vaccine in Healthy Volunteers
NCT07088822Phase 1Not yet recruiting
- Sponsor
- Medigen Biotechnology
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Live Attenuated Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of V4020 in Venezuelan equine encephalitis (VEE), sponsored by Medigen Biotechnology. Primary endpoint: Frequency and nature of adverse events at 28 days. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
V4020
03
Conditions
Venezuelan equine encephalitis (VEE)
Beyond the preview
Go deeper on NCT07088822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07088822.